Alberto Martini1, John P Sfakianos1, Lotta Renström-Koskela2, Ashkan Mortezavi3, Ugo G Falagario1, Lars Egevad4, Abolfazal Hosseini2, Reza Mehrazin1, Matthew D Galsky5, Gunnar Steineck6, N Peter Wiklund1,2. 1. Department of Urology, Icahn School of Medicine at Mount Sinai, New York, NY, USA. 2. Department of Molecular Medicine and Surgery, Section of Urology, Karolinska Institutet, Stockholm, Sweden. 3. Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden. 4. Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden. 5. Division of Hematology and Oncology, Department of Medicine, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA. 6. Sahlgrenska Academy Clinical Sciences, University of Göteborg, Gothenburg, Sweden.
Abstract
OBJECTIVE: To describe the natural history of untreated muscle-invasive bladder cancer (MIBC) and compare the oncological outcomes of treated and untreated patients. PATIENTS AND METHODS: We utilised a database encompassing all patients with newly diagnosed bladder cancer in Stockholm, Sweden between 1995 and 1996. The median follow-up for survivors was 14.4 years. Overall, 538 patients were diagnosed with bladder cancer of whom 126 had clinically localised MIBC. Patients were divided into two groups: those who received radical cystectomy or radiation therapy, and those who did not receive any form of treatment. Multivariable Cox or competing-risks regressions were adopted to predict metastasis, overall survival (OS), and cancer-specific mortality (CSM), when appropriate. Analyses were adjusted for age at diagnosis, sex, tumour stage, clinical N stage, and treatment. RESULTS: In all, 64 (51%) patients did not receive any definitive local treatment. In the untreated group, the median (interquartile range) age at diagnosis was 79 (63-83) vs 69 (63-74) years in the treated group (P < 0.001). Overall, 109 patients died during follow-up. At 6 months after diagnosis, 38% of the untreated patients had developed metastatic disease and 41% had CSM. The 5-year OS rate for untreated and treated patients was 5% (95% confidence interval [CI] 1, 12%) vs 48% (95% CI 36, 60%), respectively. Patients not receiving any treatment had a 5-year cumulative incidence of CSM of 86% (95% CI 75, 94%) vs 48% (95% CI 36, 60%) for treated patients. Untreated patients had a higher risk of progression to metastatic disease (hazard ratio [HR] 2.40, 95% CI 1.28, 4.51; P = 0.006), death from any cause (HR 2.63, 95% CI 1.65, 4.19; P < 0.001) and CSM (subdistribution HR 2.02, 95% CI 1.24, 3.30; P = 0.004). CONCLUSIONS: Untreated patients with MIBC are at very high risk of near-term CSM. These findings may help balance the risks vs benefits of integrating curative intent therapy particularly in older patients with MIBC.
OBJECTIVE: To describe the natural history of untreated muscle-invasive bladder cancer (MIBC) and compare the oncological outcomes of treated and untreated patients. PATIENTS AND METHODS: We utilised a database encompassing all patients with newly diagnosed bladder cancer in Stockholm, Sweden between 1995 and 1996. The median follow-up for survivors was 14.4 years. Overall, 538 patients were diagnosed with bladder cancer of whom 126 had clinically localised MIBC. Patients were divided into two groups: those who received radical cystectomy or radiation therapy, and those who did not receive any form of treatment. Multivariable Cox or competing-risks regressions were adopted to predict metastasis, overall survival (OS), and cancer-specific mortality (CSM), when appropriate. Analyses were adjusted for age at diagnosis, sex, tumour stage, clinical N stage, and treatment. RESULTS: In all, 64 (51%) patients did not receive any definitive local treatment. In the untreated group, the median (interquartile range) age at diagnosis was 79 (63-83) vs 69 (63-74) years in the treated group (P < 0.001). Overall, 109 patientsdied during follow-up. At 6 months after diagnosis, 38% of the untreated patients had developed metastatic disease and 41% had CSM. The 5-year OS rate for untreated and treated patients was 5% (95% confidence interval [CI] 1, 12%) vs 48% (95% CI 36, 60%), respectively. Patients not receiving any treatment had a 5-year cumulative incidence of CSM of 86% (95% CI 75, 94%) vs 48% (95% CI 36, 60%) for treated patients. Untreated patients had a higher risk of progression to metastatic disease (hazard ratio [HR] 2.40, 95% CI 1.28, 4.51; P = 0.006), death from any cause (HR 2.63, 95% CI 1.65, 4.19; P < 0.001) and CSM (subdistribution HR 2.02, 95% CI 1.24, 3.30; P = 0.004). CONCLUSIONS: Untreated patients with MIBC are at very high risk of near-term CSM. These findings may help balance the risks vs benefits of integrating curative intent therapy particularly in older patients with MIBC.
Authors: Markus Eckstein; Elena Epple; Rudolf Jung; Katrin Weigelt; Verena Lieb; Danijel Sikic; Robert Stöhr; Carol Geppert; Veronika Weyerer; Simone Bertz; Astrid Kehlen; Arndt Hartmann; Bernd Wullich; Helge Taubert; Sven Wach Journal: Cancers (Basel) Date: 2020-05-15 Impact factor: 6.639
Authors: Matthew I Bury; Natalie J Fuller; Renea M Sturm; Rebecca R Rabizadeh; Bonnie G Nolan; Milica Barac; Sonia S Edassery; Yvonne Y Chan; Arun K Sharma Journal: Sci Rep Date: 2021-01-27 Impact factor: 4.379
Authors: Raquel Carrasco; Laura Izquierdo; Antoine G van der Heijden; Juan José Lozano; Marco Franco; Mercedes Ingelmo-Torres; Fiorella L Roldan; Montserrat Llorens; María José Ribal; Lourdes Mengual; Antonio Alcaraz Journal: Sci Rep Date: 2021-03-17 Impact factor: 4.379
Authors: Chelsea K Osterman; Allison M Deal; Hannah McCloskey; Kirsten A Nyrop; Marc A Bjurlin; Hung-Jui Tan; Matthew E Nielsen; Matthew I Milowsky; Hyman B Muss; Angela B Smith Journal: J Urol Date: 2020-07-27 Impact factor: 7.450
Authors: YiHeng Du; WenHao Miao; Xiang Jiang; Jin Cao; Bo Wang; Yi Wang; Jiang Yu; XiZhi Wang; HaiTao Liu Journal: Front Oncol Date: 2021-06-03 Impact factor: 6.244
Authors: Ashkan Mortezavi; Alessio Crippa; Sebastian Edeling; Sasa Pokupic; Paolo Dell'Oglio; Francesco Montorsi; Frederiek D'Hondt; Alexandre Mottrie; Karel Decaestecker; Carl J Wijburg; Justin Collins; John D Kelly; Wei Shen Tan; Ashwin Sridhar; Hubert John; Abdullah Erdem Canda; Christian Schwentner; Erik Peder Rönmark; Peter Wiklund; Abolfazl Hosseini Journal: BJU Int Date: 2020-11-05 Impact factor: 5.588
Authors: Hendrik Jütte; Moritz Reike; Ralph M Wirtz; Maximilian Kriegmair; Philipp Erben; Karl Tully; Veronika Weyerer; Markus Eckstein; Arndt Hartmann; Sebastian Eidt; Felix Wezel; Christian Bolenz; Andrea Tannapfel; Joachim Noldus; Florian Roghmann Journal: J Pers Med Date: 2021-05-26
Authors: Katarzyna Gronostaj; Anna Katarzyna Czech; Jakub Fronczek; Tomasz Wiatr; Mikołaj Przydacz; Przemysław Dudek; Łukasz Curyło; Wojciech Szczeklik; Piotr Chłosta Journal: Cent European J Urol Date: 2020-02-27